" class="no-js "lang="en-US"> Jeff Legos - Medtech Alert
Sunday, November 10, 2024
Jeff Legos

Jeff Legos

About Jeff Legos

Dr. Jeff Legos is currently Executive Vice President and Global Head of Oncology and Hematology Development. Jeff is responsible for leading the development, registration, approval and life cycle management for Oncology and Hematology across 4 major platforms.  This includes a clinical pipeline of approximately 60+ targeted therapy, immuno-oncology, radioligand therapy (including Advanced Accelerated Applications drug development), cell & gene therapies and established product assets across a broad range of cancers and blood disorders. Dr. Legos is also the Head of Global Precision Medicine for Novartis responsible for translational medicine and diagnostic development across all therapeutic areas, including general medicine.  He has a proven track record of successfully leading large multinational teams across all functions and stages of drug development, which has resulted in more than 30 global regulatory drug and companion diagnostic approvals, including new molecular entities, product line extensions, and premarket approvals for devices.

Prior to joining Novartis in 2015, Dr. Legos was the Vice President and Global Medicines Development Leader in Oncology at GlaxoSmithKline (GSK) where he developed Tafinlar® (dabrafenib; BRAF inhibitor) and Mekinist® (trametinib; MEK inhibitor) as single agent and combination therapy for patients with BRAF V600 cancers, and  Promacta®/Revolade® (eltrombopag; TPO agonist) for patients with thrombocytopenia across a range of diseases.  He also previously held senior leadership positions in clinical development, translational medicine, and was the head of Oncology Strategy, where he was instrumental in the creation and growth of the GSK Oncology Business Unit.

Dr. Legos holds a PhD in physiology from Temple University School of Medicine, an MBA in Finance from the Villanova University School of Business, and completed his post-graduate fellowship training in pharmacology and pharmaceutical medicine. He is an author of more than 40 manuscripts and numerous abstracts published in peer-reviewed journals, and has presented at major scientific and investment conferences. Dr. Legos is also a scientific advisor to the Melanoma Research Alliance and the recipient of several government grants, academic and corporate awards.

Related Story

New Phase III Data Show Novartis Tislelizumab Significantly Extended Median Overall Survival by More Than 6 Months in First-line Advanced Esophageal Cancer in Combination With Chemotherapy

July 4 2022

Today Novartis announced results from the Phase III RATIONALE 306 trial showing tislelizumab plus chemotherapy […]

New Novartis Data Demonstrate Only Kisqali® Offers More Life in the First-line Setting for Postmenopausal HR+/HER2- Advanced Breast Cancer Patients

May 4 2022

Novartis today announced updated median overall survival (OS) results for Kisqali® (ribociclib) in combination with fulvestrant […]

Novartis Tislelizumab plus Chemotherapy Significantly Improved Overall Survival as First-line Treatment for Advanced Esophageal Cancer in Phase III Study

April 29 2022

Novartis today announced positive topline results from an interim analysis of the Phase III RATIONALE […]